ARTELO BIOSCIENCES INC (ARTL) Stock Fundamental Analysis
NASDAQ:ARTL - Nasdaq - US04301G5080 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to ARTL. ARTL was compared to 193 industry peers in the Pharmaceuticals industry. While ARTL seems to be doing ok healthwise, there are quite some concerns on its profitability. ARTL is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ARTL had negative earnings in the past year.
ARTL had a negative operating cash flow in the past year.
In the past 5 years ARTL always reported negative net income.
ARTL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ARTL (-127.82%) is worse than 83.24% of its industry peers.
ARTL's Return On Equity of -143.39% is on the low side compared to the rest of the industry. ARTL is outperformed by 65.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -127.82% | ||
| ROE | -143.39% | ||
| ROIC | N/A |
ROA(3y)-59.81%
ROA(5y)-63.82%
ROE(3y)-64.26%
ROE(5y)-70.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ARTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARTL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ARTL has been increased compared to 5 years ago.
There is no outstanding debt for ARTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ARTL has an Altman-Z score of -9.88. This is a bad value and indicates that ARTL is not financially healthy and even has some risk of bankruptcy.
ARTL has a Altman-Z score of -9.88. This is in the lower half of the industry: ARTL underperforms 75.68% of its industry peers.
ARTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.88 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 7.15 indicates that ARTL has no problem at all paying its short term obligations.
ARTL's Current ratio of 7.15 is fine compared to the rest of the industry. ARTL outperforms 75.14% of its industry peers.
A Quick Ratio of 7.15 indicates that ARTL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.15, ARTL is in the better half of the industry, outperforming 76.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.15 | ||
| Quick Ratio | 7.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.31% over the past year.
EPS 1Y (TTM)12.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, ARTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.71% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.98%
EPS Next 2Y30.81%
EPS Next 3Y21.25%
EPS Next 5Y13.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ARTL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARTL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ARTL's earnings are expected to grow with 21.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.81%
EPS Next 3Y21.25%
5. Dividend
5.1 Amount
No dividends for ARTL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ARTL (2/21/2025, 8:01:47 PM)
1.16
-0.04 (-3.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.15%
Inst Owner Change-41.13%
Ins Owners0.83%
Ins Owner Change0%
Market Cap3.75M
Analysts82.22
Price Target5.44 (368.97%)
Short Float %0.27%
Short Ratio0.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.55%
Min EPS beat(2)13.15%
Max EPS beat(2)25.94%
EPS beat(4)3
Avg EPS beat(4)-4.14%
Min EPS beat(4)-83.16%
Max EPS beat(4)27.52%
EPS beat(8)5
Avg EPS beat(8)-6.04%
EPS beat(12)7
Avg EPS beat(12)-1.88%
EPS beat(16)9
Avg EPS beat(16)-1.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-61.9%
PT rev (3m)-61.9%
EPS NQ rev (1m)-19.09%
EPS NQ rev (3m)-18.02%
EPS NY rev (1m)-12.62%
EPS NY rev (3m)5.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.59 | ||
| P/tB | 0.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.92
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-2.59
FCFYN/A
OCF(TTM)-2.59
OCFYN/A
SpS0
BVpS1.97
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -127.82% | ||
| ROE | -143.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-59.81%
ROA(5y)-63.82%
ROE(3y)-64.26%
ROE(5y)-70.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.15 | ||
| Quick Ratio | 7.15 | ||
| Altman-Z | -9.88 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.83%
EPS Next Y21.98%
EPS Next 2Y30.81%
EPS Next 3Y21.25%
EPS Next 5Y13.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-272.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-272.44%
OCF growth 3YN/A
OCF growth 5YN/A